Compound 31543 Calcitriol not checked
BPGbio · BPM31543 Topical Solution
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Chemotherapy-Induced Alopecia
- Main trialPhase 1
- “The goal of this clinical trial is to learn if Compound 31543 (topical calcitriol) for treatment of hair-loss in patients with a diagnosis of breast cancer, gynecologic cancer or sarcomas receiving a taxane-based chemotherapy is safe. The main questions it aims to answer are: * What medical problems do participants have when using compound 31543? * How much Compound 31543 is in blood after treatment? * How much hair is lost during treatment? Participants will: * Apply Compound 31543 to their scalp twice a day, starting at least 5 days before starting chemotherapy for at least 3 months or…”In the company’s words, NCT01588522 on ClinicalTrials.gov
- Other names
- Calcitriol · BPM31543 Topical Solution
Other drugs for Chemotherapy-Induced Alopecia
- RitlecitinibPfizer · Phase 3
- VDPHL01Veradermics, Inc. · Phase 3
- OMA102EMS · Phase 3
- DA-001Applied Biology, Inc. · Phase 2/3
- DeuruxolitinibSun Pharma · Phase 3
- CKD-843Chong Kun Dang Pharmaceutical · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 16 Feb 2017 | Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Chemotherapy-Induced Alopecia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026